| 000 | 05362cas|a2200517 a 4500 | ||
|---|---|---|---|
| 005 | 20260817172422.0 | ||
| 008 | 011213s2001 th uu|m rtt 0| a1engxd | ||
| 035 | _a.b11841370 | ||
| 099 | 9 | _aAIT Thesis no.SM-01-05 | |
| 100 | 1 | _aEmond, Marie-Hèléne | |
| 245 | 1 | 0 |
_aChallenges and opportunities for developing countries in reforming the intellectual property regime within the WTO : _bapplication to pharmaceuticals in Thailand |
| 260 |
_aBangkok : _bAsian Institute of Technology, _c2001 |
||
| 300 | _a119, [2] leaves | ||
| 490 | 1 |
_aThesis ; _vno. SM-01-05 |
|
| 500 | _aA thesis submitted in partial fulfillment of the requirements for the degree of Master in Business Administration, School of Management | ||
| 502 | _aThesis (M.B.A.) - Asian Institute of Technology, 2001 | ||
| 520 | _aThe outcome of our thesis consists in two frameworks, i.e. a "synergies framework" and a "compulsory licensing framework". First, three public policy tools, namely petty patents and compulsory licensing when authorizing parallel trade have been proved as possible opportunities for developing countries facing the strengthening of their intellectual property regime further to the TRIPS Agreement. The synergies framework identifies possible synergies between those three tools implemented in the Thai Patent Act as to counterbalance abusive market monopolies situation by improving access to products on the domestic market at reasonable price, when facilitating the technology transfer process. The compulsory licensing framework addresses more specifically compulsory licensing. It has been designed based on the case study of antiretroviral pharmaceuticals in Thailand. The first task was to define an abusive market monopoly situation implying excessive selling prices. Does the price of a pharmaceutical depend on: the Thai (or any developing country) market taking into account its solvability and its urgent need for the medicine, OR the risk and cost of R&D efforts exerted by pharmaceutical companies benefiting from the patent protection? The issue appeared as complex as we identified factors than the price relating to the national situation such as the health infrastructure. The lack of transparency from the pharmaceutical companies did not help in assessing the effective R&D cost and risk and the relating necessary price level as to reward companies for their efforts. The objective was to assess which level of effective compulsory licensing implementation would have challenged the positive dynamic of patent protection. Besides any philosophical or human rights perspectives generating the current hot debate about access to medicines, our second framework highlights economical, cultural, political and technical factors, which influence the compulsory licensing effort at the national and international levels. Our scheme is based on the ddl case review but also on our attempt to generalize the compulsory licensing process to other pharmaceuticals and possibly other industrial sectors in the developing world. We have finally recommended how to orientate the various key factors as to positively influence the compulsory licensing process. The ultimate objective of compulsory licensing in a developing country does not reside only in the access to reasonable p1ices but also in the underlying but essential transfer of technology. | ||
| 650 | 0 |
_aIntellectual property _zDeveloping countries |
|
| 650 | 0 |
_aPharmaceutical industry _zThailand |
|
| 700 | 1 |
_aIgel, Barbara, _eChairperson |
|
| 700 | 1 |
_aBroustai, Joel Francois, _eExamination Committee |
|
| 700 | 1 |
_aVidon, Patiice, _eExamination committee |
|
| 700 | 1 |
_aBasant, Rakesh, _eExamination committee |
|
| 710 | 2 |
_aEuropean Commission of the European Union (PTS Program), _eScholarship donor |
|
| 810 | 2 |
_aAsian Institute of Technology. _tThesis ; _vno. SM-01-05 |
|
| 856 |
_3Full-Text _uhttp://203.159.5.9/ait-thesis/detail.php?q=B09362 |
||
| 907 |
_a.b11841370 _bmnait _cu |
||
| 902 | _a241009 | ||
| 998 |
_b0 _c011213 _dm _ea _fu _g0 |
||
| 945 | _lmnait | ||
| 945 | _lmnait | ||
| 945 | _lmnarc | ||
| 945 | _lmnarc | ||
| 945 | _lmnarc | ||
| 945 | _lmnarc | ||
| 942 | _c20 | ||
| 942 | _c22 | ||
| 942 | _c40 | ||
| 909 |
_aBarcode : 30050120998082 _bCREATED : 2001-12-13 _cRECORD # : i12264891 _dLPATRON : 1019926 _eLCHKIN : 2008-01-02 _f# RENEWALS : 0 _g# OVERDUE : 0 _hIUSE3 : 0 _iTOT CHKOUT : 1 _jTOT RENEW : 0 |
||
| 909 |
_aBarcode : 30050120998090 _bCREATED : 2001-12-13 _cRECORD # : i12264908 _dLPATRON : 1018569 _eLCHKIN : 2007-08-08 _f# RENEWALS : 0 _g# OVERDUE : 0 _hIUSE3 : 0 _iTOT CHKOUT : 2 _jTOT RENEW : 6 |
||
| 909 |
_aBarcode : 30050120551709 _bCREATED : 2014-10-04 _cRECORD # : i12789112 _dLPATRON : 0 _eLCHKIN : - _f# RENEWALS : 0 _g# OVERDUE : 0 _hIUSE3 : 0 _iTOT CHKOUT : 0 _jTOT RENEW : 0 |
||
| 909 |
_aBarcode : 30050120221998 _bCREATED : 2016-03-31 _cRECORD # : i12917229 _dLPATRON : 0 _eLCHKIN : - _f# RENEWALS : 0 _g# OVERDUE : 0 _hIUSE3 : 0 _iTOT CHKOUT : 0 _jTOT RENEW : 0 |
||
| 909 |
_aBarcode : 30050120907208 _bCREATED : 2020-01-29 _cRECORD # : i13253311 _dLPATRON : 0 _eLCHKIN : - _f# RENEWALS : 0 _g# OVERDUE : 0 _hIUSE3 : 1 _iTOT CHKOUT : 0 _jTOT RENEW : 0 |
||
| 909 |
_aBarcode : 30050121070956 _bCREATED : 2023-06-27 _cRECORD # : i13453774 _dLPATRON : 0 _eLCHKIN : - _f# RENEWALS : 0 _g# OVERDUE : 0 _hIUSE3 : 0 _iTOT CHKOUT : 0 _jTOT RENEW : 0 |
||
| 999 |
_c16055 _d16055 |
||